Furthermore, weight loss injections are typically reserved for individuals with a BMI of 30 or above, or a BMI of 27 with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol levels
The SURMOUNT-5 trial published in the New England Journal of Medicine in May 2025 was the first randomized, head-to-head comparison of the two medications in patients with obesity but without type 2 diabetes
If it turns out to be true, it would make Ozempic and drugs like it one of the biggest medical breakthroughs of the century, a treatment for three of the most serious modern health dilemmas diabetes, obesity and addiction.
May 2026: A May 1, 2026 update reported that the federal GLP-1 multidistrict litigation now includes 3,636 pending cases, with Mounjaro claims still making up a large share of the docket
Not all insurance plans cover this, but it is worth asking